Lidocaine Clinical Trial
Official title:
The Evaluation of the Safety and Effectiveness of ANIMERS Chiara LA and JUVÉDERM VOLUMA® for Aging Mid-Face
NCT number | NCT04622085 |
Other study ID # | RDCT-AHSK |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 6, 2021 |
Est. completion date | May 9, 2023 |
Verified date | October 2023 |
Source | SciVision Biotech Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to evaluate the safety and effectiveness for the correction of aging mid-face of treatment group compared with the active control group.
Status | Completed |
Enrollment | 20 |
Est. completion date | May 9, 2023 |
Est. primary completion date | November 4, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Age 30 to 60 years of male or female 2. MidFace Volume Deficit Scale (MFVDS) of midface graded 2 to 5 by evaluator. Exclusion Criteria: 1. Injection site with infection or other skin diseases present which may affect the evaluation 2. With medical history of chromatosis, discoloration, keloid formation, hypertrophic scarring at midface 3. With permanent implants or planning to receive permanent implants during the study period at the injection sites 4. Hyaluronate facial dermal implant injection or other impermanent dermal fillers injection at injection sites within the past 6 months 5. With under-eye facial Botox or fat injection within the past 6 months or planning to receive under-eye facial Botox or fat injection during the study period 6. With Major surgery 3 months before the start of the trial 7. With under-eye facial chemical or lasers peeling, non-invasive skin tightening, thermocool within the past 3 months or planning to receive these aesthetic procedures during the study period 8. With systemic immunosuppressive therapy or systemic corticosteroids within the past 2 months or planning to receive these therapies during the study period (subjects who have received inhaled/intranasal corticosteroids could be considered to include.) 9. With clinical meaningful coagulation disorders, underdoing anticoagulant treatment or within the past 10 days, or taking blood circulation promotion and blood stasis movement medications 10. With epilepsy or porphyria 11. With congenital or idiopathic methemoglobinemia or glucose-6-phosphate dehydrogenase deficiency 12. With analgesic dependence, analgesics within the past 2 weeks or planning to receive analgesics during the study period 13. With history of hypersensitivity or allergy to lidocaine, amide anesthetics, hyaluronic acid or any component of the device; Gram-positive bacterial or Streptococcus proteins; other severe hypersensitivity history unsuitable for participating in the study 14. Planning to undergo any surgery which may cause significant body weight change (such as bariatric surgery) or take any medication which may cause significant body weight change 15. Pregnant, planning pregnancy or in breastfeeding females 16. Participated in clinical study of other device or drug and have not terminated within the past 30 days -Other circumstances which judged to be unsuitable for participating in the study by the investigator |
Country | Name | City | State |
---|---|---|---|
Taiwan | Shin Kong Wu Ho-Su Memorial Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
SciVision Biotech Inc. |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate of a = 1 Grade improvement on the assessment of MidFace Volume Deficit Scale (MFVDS) | The response rate is = 1 Grade improvement on the assessment of MidFace Volume Deficit Scale (MFVDS) as assessed by the evaluator at 6 months.
Evaluators assess the midface volume deficit scale (MFVDS) on site with 5 graded scale, 0 to 5 was represented 'Fullness' to 'Severe concavity'. |
6 months post-injection | |
Secondary | Face fullness value evaluated by the digital image scoring system after injection and post 1, 3, 6, 12, 18, 24 months. | The digital image scoring system analyzes the volume change (ml). A higher score means more volume increased in the midface. | Immediate, 1, 3, 6, 12, 18 and 24 months post-injection | |
Secondary | MFVDS value evaluated by blinded-evaluator after injection and 1, 3, 6, 12, 18, 24 months. | Evaluators assess the midface volume deficit scale on site with 5 graded scale, 0 to 5 was represented 'Fullness' to 'Severe concavity'. | Immediate, 1, 3, 6, 12, 18 and 24 months post-injection | |
Secondary | A Response rate of MFVDS value evaluated by blinded-evaluator after injection and 1, 3, 6, 12, 18, 24 months. | The response rate is = 1 Grade improvement on the assessment of the MidFace Volume Deficit Scale (MFVDS) as assessed by the evaluator after injection and 1, 3, 6, 12, 18, 24 months.
Evaluators assess the midface volume deficit scale (MFVDS) on site with 5 graded scale, 0 to 5 was represented 'Fullness' to 'Severe concavity'. |
Immediate, 1, 3, 6, 12, 18 and 24 months post-injection | |
Secondary | GAIS evaluated photographically by blinded-evaluator after injection and 1, 3, 6, 12, 18, 24 months. | Evaluators and subjects assess the improvement of correction with 5 graded scale,1 to 5 was represented 'exceptional improvement' to 'worsened'. | Immediate, 1, 3, 6, 12, 18 and 24 months post-injection | |
Secondary | VAS pain evaluated immediately and 15, 30, 45 and 60 minutes after injection | The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'. | Immediate,15, 30, 45 and 60 minutes post-injection | |
Secondary | Adverse events reported during the study period | The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period. | Immediate, 1, 3, 6, 12, 18 and 24 months post-injection | |
Secondary | Serious adverse events reported during the study period | The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period. | Immediate, 1, 3, 6, 12, 18 and 24 months post-injection | |
Secondary | Device failure reported before injection | The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period. | Before injection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06355817 -
Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration
|
N/A | |
Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
Completed |
NCT04692896 -
Effect of Different Concentrations of Lidocaine in Relieving Pain in Wide Awake Hand Surgery Using Tumescence
|
Phase 1 | |
Recruiting |
NCT06088875 -
Nebulization Versus Spray-as-You-Go Airway Topical Anesthesia Using Dexmedetomidine and Lidocaine Mixture During Awake Flexible Fiberoptic Intubation in Temporomandibular Ankylosis
|
N/A | |
Recruiting |
NCT04169854 -
Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain
|
Phase 3 | |
Completed |
NCT04076865 -
Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch
|
N/A | |
Completed |
NCT02987985 -
Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy
|
Phase 3 | |
Recruiting |
NCT05089526 -
Opioid-free Anesthesia in Laparoscopic Cholecystectomies
|
N/A | |
Recruiting |
NCT03871478 -
Comparing the Efficacy of Local Anesthetics in Mohs Surgery
|
N/A | |
Recruiting |
NCT03673163 -
Lidocaine Infusion for Pain After Herniotomy
|
N/A | |
Recruiting |
NCT03666299 -
Lidocaine Infusion for Postthoracotomy Pain Syndrome
|
N/A | |
Recruiting |
NCT05158348 -
A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine
|
Phase 3 | |
Completed |
NCT06135688 -
Effects of Lidocaine Bolus and Infusion on Bispectral Index Values and Spectrum During Anesthesia Maintenance
|
||
Completed |
NCT04008433 -
Median Effective Dose of Lidocaine for the Prevention of Pain Caused by the Injection of Propofol Formulated With Medium-/Long-chain Triglycerides
|
N/A | |
Recruiting |
NCT04622904 -
Lidocaine and Magnesium and Ketamine in Gynecological Surgery
|
N/A | |
Recruiting |
NCT05717361 -
Opioid Sparing Anesthesia in Cervical Spine Surgery
|
N/A | |
Withdrawn |
NCT04359017 -
Systemic Absorption of Lidocaine After Hematoma Block
|
Phase 4 | |
Recruiting |
NCT04144933 -
Effect of Multimodal Opioid-free Anesthesia on Return of Bowel Function in Laparoscopic Colorectal Surgery
|
Phase 3 | |
Recruiting |
NCT05243940 -
Opioid-free Anesthesia in Thyroidectomies
|
N/A | |
Completed |
NCT05484687 -
Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors
|
N/A |